Thursday, January 26, 2006 11:15:46 PM
AP, Thursday January 26, 1:09 pm ET
Byetta Sales Push Amylin Pharmaceuticals Shares Higher Despite Wider-Than-Expected 4Q Loss
NEW YORK (AP) -- Amylin Pharmaceuticals Inc. shares edged higher Thursday after Eli Lilly & Co. released particularly strong sales for the diabetes therapy the drug makers developed together.
The Byetta drug, used by Type 2 diabetics to help control their blood sugar levels, was approved by the Food and Drug Administration in June. It posted fourth-quarter sales of $49 million, bringing its total since launch to $74.6 million.
Amylin, which receives 50 percent of the gross profit from Byetta, saw its shares rise 83 cents, or 2 percent, to $43.20 in afternoon trading on the Nasdaq. Lilly shares fell 17 cents to $57 on the New York Stock Exchange.
San Diego-based Amylin said earlier it will post a fourth-quarter loss of $66 million to $69 million, or 60 cents to 63 cents per share, because of higher costs that offset the Byetta revenue. Some of the increased expenses come from investment in a once-weekly formulation of Byetta.
Analysts surveyed by Thomson Financial expect a loss of 59 cents per share.
Amylin plans to release more detailed fourth-quarter results on Feb. 9. The company's third-quarter revenue totaled $25.9 million.
http://biz.yahoo.com/ap/060126/amylin_outlook.html?.v=1
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM